Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drugs, Antidepressant Drugs, Opioids, Non-Narcotics, and Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, and Other Indications), Pain Type (Chronic and Acute) : Global Opportunity Analysis and Industry Forecast, 2019–2027
The global pain management drugs market was valued at $71,431.85 million in 2019, and is projected to reach $91,649.16 million by 2027, registering a CAGR of 3.8%. Pain is a distressing sensory and emotional sensation, which is caused by tissue injury or disease. Moreover, different disorders may cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer. The length of the pain would range from acute pain for short term to chronic pain for long term. Acute pain is a sudden onset of pain when chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. Pain management involves reducing or treating pain by using a given range of medications. There are several medicines available, which provide pain relief through a variety of physiological mechanisms such as targeting nociceptors.
Rise in geriatric population is the major factor that drives growth of the global pain management market, as aged people are more prone to suffer from joint pain and other chronic conditions. For instance, prevalence of chronic diseases such as cancer is on the rise. As per the National Cancer Institute, almost 20 to 50% of people with cancer suffer from pain. Around 80% of patients with advanced stage cancer suffer from moderate to severe pain. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.
The global pain management drugs market is segmented on the basis of drug class, indication, and region On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics. On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis and others. Based on pain type, the market is segmented into chronic pain and acute pain. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
By Drug Class
Rise in geriatric population is the major factor that drives growth of the global pain management market, as aged people are more prone to suffer from joint pain and other chronic conditions. For instance, prevalence of chronic diseases such as cancer is on the rise. As per the National Cancer Institute, almost 20 to 50% of people with cancer suffer from pain. Around 80% of patients with advanced stage cancer suffer from moderate to severe pain. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.
The global pain management drugs market is segmented on the basis of drug class, indication, and region On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics. On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis and others. Based on pain type, the market is segmented into chronic pain and acute pain. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global pain management drug market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- The market forecast is studied from 2020 to 2027
- Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products of pain management used across the globe.
- Key market players and their strategies have been analysed to understand the competitive outlook of the market.
By Drug Class
- NSAIDs
- Anesthetics
- Anticonvulsants
- Anti-migraine Agents
- Antidepressants
- Opioids
- Nonnarcotic Analgesics
- Arthritic Pain
- Neuropathic Pain
- Cancer Pain
- Chronic Back Pain
- Postoperative Pain
- Migraine
- Fibromyalgia
- Bone fracture
- Muscle sprain
- Acute appendicitis
- Others
- Chronic pain
- Acute pain
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Abbott Laboratories
- Eli Lilly & Company
- Endo Health Solutions, Inc.,
- GlaxoSmithKline Plc.
- Johnson & Johnson
- Merck & Co. Inc.
- Mylan NV.
- Novartis AG
- Pfizer, Inc.
- Purdue Pharma L.P.
- Allergen Inc.
- Bayer AG
- Bristol-Myers Squibb
- Boehringer Ingelheim
- Sorrento Therapeutics
- Valeant Pharmaceuticals International Inc.
- WEX Pharmaceuticals
- Zynerba Pharmaceuticals.
CHAPTER 1: INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
1.4.4.Primary research
CHAPTER 2: EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top winning strategies
3.3.Top player positioning
3.4.Porter’s five force analysis for North America
3.5.Government regulations
3.6.Market dynamics
3.6.1.Drivers
3.6.1.1.Rise in incidences of chronic diseases
3.6.1.2.Favorable regulatory scenario
3.6.1.3.Increase in geriatric population
3.6.2.Restraints
3.6.2.1.Availability of alternative therapies
3.6.2.2.Drug exploitation
3.6.2.3.Patent expiration of prescription drugs
3.6.3.Opportunities
3.6.3.1.Advancements in drug development
3.6.3.2.Untapped markets in developing economies
3.7.North America pricing for pain management drugs
3.8.Standard of care for pain management in North America
3.9.Reimbursement scenario in North America
3.10.COVID-19 impact analysis for North America Pain Management Drugs
CHAPTER 4: GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS
4.1.Overview
4.1.1.Market size and forecast
4.2.NSAIDS
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.2.4.Market analysis, by country
4.3.Anesthetics
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Anticonvulsants
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Antimigraine drug
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.6.Antidepressant drugs
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country
4.7.Opioids
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country
4.8.Non-narcotic analgesics
4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by region
4.8.3.Market analysis, by country
CHAPTER 5: GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Arthritic pain
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Neuropathic pain
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Cancer pain
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Chronic back pain
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Post-operative pain
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
5.7.Migraine
5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country
5.8.Fibromyalgia
5.8.1.Market size and forecast, by region
5.8.2.Market analysis, by country
5.9.Bone fracture
5.9.1.Market size and forecast, by region
5.9.2.Market analysis, by country
5.10.Muscle sprain/strain
5.10.1.Market size and forecast, by region
5.10.2.Market analysis, by country
5.11.Acute appendicitis
5.11.1.Market size and forecast, by region
5.11.2.Market analysis, by country
5.12.Others
5.12.1.Market size and forecast, by region
5.12.2.Market analysis, by country
CHAPTER 6: PAIN MANAGEMENT DRUGS, BY PAIN TYPE
6.1.Overview
6.1.1.Market size and forecast
6.2.Chronic pain
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Acute pain
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
CHAPTER 7: PAIN MANAGEMENT DRUGS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America pain management drugs market, by country
7.2.2.1.U.S. Pain management drugs market, by drug class
7.2.2.2.U.S pain management drugs market, by indications
7.2.2.3.U.S pain management drugs market, by pain type
7.2.2.4.Canada pain management drugs market, by drug class
7.2.2.5.Canada pain management drugs market, by indication
7.2.2.6.Canada pain management drugs market, by pain type
7.2.2.7.Mexico pain management drugs market, by drug class
7.2.2.8.Mexico pain management drugs market, by indication
7.2.2.9.Mexico pain management drugs market, by pain type
7.2.3.North America pain management drugs market, by drug class
7.2.4.North America pain management drugs market, by indication
7.2.5.North America pain management drugs market, by pain type
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe pain management drugs market, by country
7.3.2.1.UK pain management drugs market, by drug class
7.3.2.2.UK pain management drugs market, by indication
7.3.2.3.UK pain management drugs market, by pain type
7.3.2.4.Germany pain management drugs market, by drug class
7.3.2.5.Germany pain management drugs market, by indication
7.3.2.6.Germany pain management drugs market, by pain type
7.3.2.7.France pain management drugs market, by drug class
7.3.2.8.France pain management drugs market, by indication
7.3.2.9.France pain management drugs market, by pain type
7.3.2.10.Italy pain management drugs market, by drug class
7.3.2.11.Italy pain management drugs market, by indication
7.3.2.12.Italy pain management drugs market, by pain type
7.3.2.13.Spain management drugs market, by drug class
7.3.2.14.Spain Management Drugs Market, by indication
7.3.2.15.Spain management drugs market, by pain type
7.3.2.16.Rest of Europe pain management drugs market, by drug class
7.3.2.17.Rest of Europe Pain Management Drugs Market, by indication
7.3.2.18.Rest of Europe pain management drugs market, by pain type
7.3.3.Europe pain management drugs market, by drug class
7.3.4.Europe pain management drugs market, by indication
7.3.5.Europe pain management drugs market, by pain type
7.4.Asia Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific pain management drugs market, by country
7.4.2.1.Japan pain management drugs market, by drug class
7.4.2.2.Japan pain management drugs market, by indications
7.4.2.3.Japan Pain Management Drugs Market, by pain type
7.4.2.4.China pain management drugs market, by drug class
7.4.2.5.China pain management drugs market, by indications
7.4.2.6.China pain management drugs market, by pain type
7.4.2.7.Australia pain management drugs market, by drug class
7.4.2.8.Australia pain management drugs market, by indications
7.4.2.9.Australia pain management drugs market, by pain type
7.4.2.10.India pain management drugs market, by drug class
7.4.2.11.India pain management drugs market, by indications
7.4.2.12.India pain management drugs market, by pain type
7.4.2.13.Rest of Asia-Pacific pain management drugs market, by drug class
7.4.2.14.Rest of Asia-Pacific pain management drugs market, by indications
7.4.2.15.Rest of Asia-Pacific pain management drugs market, by pain type
7.4.3.Asia-Pacific pain management drugs market, by drug Class1
7.4.4.Asia-Pacific pain management drugs market, by indication
7.4.5.Asia-Pacific pain management drugs market, by pain type
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA pain management drugs market, by country
7.5.2.1.Brazil pain management drugs market, by drug class
7.5.2.2.Brazil pain management drugs market, by indication
7.5.2.3.Brazil pain management drugs market, by pain type
7.5.2.4.Saudi Arabia pain management drugs market, by drug class
7.5.2.5.Saudi Arabia pain management drugs market, by indication
7.5.2.6.Saudi Arabia pain management drugs market, by pain type
7.5.2.7.South Africa pain management drugs Market, by drug class
7.5.2.8.South Africa Pain Management Drugs Market, by indication
7.5.2.9.South Africa pain management drugs market, by pain type
7.5.2.10.Rest of LAMEA pain management drugs market, by drug class
7.5.2.11.Rest of LAMEA pain management drugs market, by indication
7.5.2.12.Rest of LAMEA pain management drugs market, by pain type
7.5.3.LAMEA pain management drugs market, by drug Class
7.5.4.LAMEA pain management drugs market, by indication
7.5.5.LAMEA pain management drugs market, by drug Class
CHAPTER 8: COMPANY PROFILES
8.1.ABBOTT LABORATORIES
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.ELI LILY AND COMPANY
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.ENDO HEALTH SOLUTIONS, INC. (ENDO INTERNATIONAL PLC.)
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.GLAXOSMITHKLINE PLC (GSK)
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.JOHNSON & JOHNSON
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.6.MERCK & CO., INC.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.MYLAN N.V.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.NOVARTIS INTERNATIONAL AG
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.PFIZER INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.PURDUE PHARMA L.P.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Key strategic moves and developments
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
1.4.4.Primary research
CHAPTER 2: EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top winning strategies
3.3.Top player positioning
3.4.Porter’s five force analysis for North America
3.5.Government regulations
3.6.Market dynamics
3.6.1.Drivers
3.6.1.1.Rise in incidences of chronic diseases
3.6.1.2.Favorable regulatory scenario
3.6.1.3.Increase in geriatric population
3.6.2.Restraints
3.6.2.1.Availability of alternative therapies
3.6.2.2.Drug exploitation
3.6.2.3.Patent expiration of prescription drugs
3.6.3.Opportunities
3.6.3.1.Advancements in drug development
3.6.3.2.Untapped markets in developing economies
3.7.North America pricing for pain management drugs
3.8.Standard of care for pain management in North America
3.9.Reimbursement scenario in North America
3.10.COVID-19 impact analysis for North America Pain Management Drugs
CHAPTER 4: GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS
4.1.Overview
4.1.1.Market size and forecast
4.2.NSAIDS
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.2.4.Market analysis, by country
4.3.Anesthetics
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Anticonvulsants
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Antimigraine drug
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.6.Antidepressant drugs
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country
4.7.Opioids
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country
4.8.Non-narcotic analgesics
4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by region
4.8.3.Market analysis, by country
CHAPTER 5: GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Arthritic pain
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Neuropathic pain
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Cancer pain
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Chronic back pain
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Post-operative pain
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
5.7.Migraine
5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country
5.8.Fibromyalgia
5.8.1.Market size and forecast, by region
5.8.2.Market analysis, by country
5.9.Bone fracture
5.9.1.Market size and forecast, by region
5.9.2.Market analysis, by country
5.10.Muscle sprain/strain
5.10.1.Market size and forecast, by region
5.10.2.Market analysis, by country
5.11.Acute appendicitis
5.11.1.Market size and forecast, by region
5.11.2.Market analysis, by country
5.12.Others
5.12.1.Market size and forecast, by region
5.12.2.Market analysis, by country
CHAPTER 6: PAIN MANAGEMENT DRUGS, BY PAIN TYPE
6.1.Overview
6.1.1.Market size and forecast
6.2.Chronic pain
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Acute pain
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
CHAPTER 7: PAIN MANAGEMENT DRUGS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America pain management drugs market, by country
7.2.2.1.U.S. Pain management drugs market, by drug class
7.2.2.2.U.S pain management drugs market, by indications
7.2.2.3.U.S pain management drugs market, by pain type
7.2.2.4.Canada pain management drugs market, by drug class
7.2.2.5.Canada pain management drugs market, by indication
7.2.2.6.Canada pain management drugs market, by pain type
7.2.2.7.Mexico pain management drugs market, by drug class
7.2.2.8.Mexico pain management drugs market, by indication
7.2.2.9.Mexico pain management drugs market, by pain type
7.2.3.North America pain management drugs market, by drug class
7.2.4.North America pain management drugs market, by indication
7.2.5.North America pain management drugs market, by pain type
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe pain management drugs market, by country
7.3.2.1.UK pain management drugs market, by drug class
7.3.2.2.UK pain management drugs market, by indication
7.3.2.3.UK pain management drugs market, by pain type
7.3.2.4.Germany pain management drugs market, by drug class
7.3.2.5.Germany pain management drugs market, by indication
7.3.2.6.Germany pain management drugs market, by pain type
7.3.2.7.France pain management drugs market, by drug class
7.3.2.8.France pain management drugs market, by indication
7.3.2.9.France pain management drugs market, by pain type
7.3.2.10.Italy pain management drugs market, by drug class
7.3.2.11.Italy pain management drugs market, by indication
7.3.2.12.Italy pain management drugs market, by pain type
7.3.2.13.Spain management drugs market, by drug class
7.3.2.14.Spain Management Drugs Market, by indication
7.3.2.15.Spain management drugs market, by pain type
7.3.2.16.Rest of Europe pain management drugs market, by drug class
7.3.2.17.Rest of Europe Pain Management Drugs Market, by indication
7.3.2.18.Rest of Europe pain management drugs market, by pain type
7.3.3.Europe pain management drugs market, by drug class
7.3.4.Europe pain management drugs market, by indication
7.3.5.Europe pain management drugs market, by pain type
7.4.Asia Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific pain management drugs market, by country
7.4.2.1.Japan pain management drugs market, by drug class
7.4.2.2.Japan pain management drugs market, by indications
7.4.2.3.Japan Pain Management Drugs Market, by pain type
7.4.2.4.China pain management drugs market, by drug class
7.4.2.5.China pain management drugs market, by indications
7.4.2.6.China pain management drugs market, by pain type
7.4.2.7.Australia pain management drugs market, by drug class
7.4.2.8.Australia pain management drugs market, by indications
7.4.2.9.Australia pain management drugs market, by pain type
7.4.2.10.India pain management drugs market, by drug class
7.4.2.11.India pain management drugs market, by indications
7.4.2.12.India pain management drugs market, by pain type
7.4.2.13.Rest of Asia-Pacific pain management drugs market, by drug class
7.4.2.14.Rest of Asia-Pacific pain management drugs market, by indications
7.4.2.15.Rest of Asia-Pacific pain management drugs market, by pain type
7.4.3.Asia-Pacific pain management drugs market, by drug Class1
7.4.4.Asia-Pacific pain management drugs market, by indication
7.4.5.Asia-Pacific pain management drugs market, by pain type
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA pain management drugs market, by country
7.5.2.1.Brazil pain management drugs market, by drug class
7.5.2.2.Brazil pain management drugs market, by indication
7.5.2.3.Brazil pain management drugs market, by pain type
7.5.2.4.Saudi Arabia pain management drugs market, by drug class
7.5.2.5.Saudi Arabia pain management drugs market, by indication
7.5.2.6.Saudi Arabia pain management drugs market, by pain type
7.5.2.7.South Africa pain management drugs Market, by drug class
7.5.2.8.South Africa Pain Management Drugs Market, by indication
7.5.2.9.South Africa pain management drugs market, by pain type
7.5.2.10.Rest of LAMEA pain management drugs market, by drug class
7.5.2.11.Rest of LAMEA pain management drugs market, by indication
7.5.2.12.Rest of LAMEA pain management drugs market, by pain type
7.5.3.LAMEA pain management drugs market, by drug Class
7.5.4.LAMEA pain management drugs market, by indication
7.5.5.LAMEA pain management drugs market, by drug Class
CHAPTER 8: COMPANY PROFILES
8.1.ABBOTT LABORATORIES
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.ELI LILY AND COMPANY
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.ENDO HEALTH SOLUTIONS, INC. (ENDO INTERNATIONAL PLC.)
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.GLAXOSMITHKLINE PLC (GSK)
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments
8.5.JOHNSON & JOHNSON
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.6.MERCK & CO., INC.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.MYLAN N.V.
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.NOVARTIS INTERNATIONAL AG
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.PFIZER INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments
8.10.PURDUE PHARMA L.P.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Key strategic moves and developments
LIST OF TABLES
TABLE 01.PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 02.PAIN MANAGEMENT DRUGS MARKET, BY NSAIDS, BY REGION, 2019–2027 ($MILLION)
TABLE 03.PAIN MANAGEMENT DRUGS MARKET, BY ANESTHETIC, BY REGION, 2019–2027 ($MILLION)
TABLE 04.PAIN MANAGEMENT DRUGS MARKET, BY ANTICONVULSANT, BY REGION, 2019–2027 ($MILLION)
TABLE 05.PAIN MANAGEMENT DRUGS MARKET, BY ANTIMIGRAINE DRUG, BY REGION, 2019–2027 ($MILLION)
TABLE 06.PAIN MANAGEMENT DRUGS MARKET, BY ANTIDEPRESSANT DRUGS, BY REGION, 2019–2027 ($MILLION)
TABLE 07.PAIN MANAGEMENT DRUGS MARKET, BY OPIOIDS, BY REGION, 2019–2027 ($MILLION)
TABLE 08.PAIN MANAGEMENT DRUGS MARKET, BY NON-NARCOTIC ANALGESICS, BY REGION, 2019–2027 ($MILLION)
TABLE 09.PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 10.PAIN MANAGEMENT DRUGS MARKET, BY ARTHMITIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 11.PAIN MANAGEMENT DRUGS MARKET, BY NEUROPATHIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 12.PAIN MANAGEMENT DRUGS MARKET, BY CANCER PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 13.PAIN MANAGEMENT DRUGS MARKET, BY CHRONIC BACK PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 14.PAIN MANAGEMENT DRUGS MARKET, BY POST-OPERATIVE PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 15.PAIN MANAGEMENT DRUGS MARKET, BY MIGRAINE, BY REGION, 2019–2027 ($MILLION)
TABLE 16.PAIN MANAGEMENT DRUGS MARKET, BY FIBROMYALGIA, BY REGION, 2019–2027 ($MILLION)
TABLE 17.PAIN MANAGEMENT DRUGS MARKET, BY BONE FRACTURE, BY REGION, 2019–2027 ($MILLION)
TABLE 18.PAIN MANAGEMENT DRUGS MARKET, BY MUSCLE SPRAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 19.PAIN MANAGEMENT DRUGS MARKET, BY ACUTE APPENDICITIS, BY REGION, 2019–2027 ($MILLION)
TABLE 20.PAIN MANAGEMENT DRUGS MARKET, BY OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 21.PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 22.PAIN MANAGEMENT DRUGS MARKET, BY CHRONIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 23.PAIN MANAGEMENT DRUGS MARKET, BY ACUTE PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 24.GLOBAL PAIN MANAGEMENT DRUGS MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 25.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 26.U.S. PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 27.U.S. PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 28.U.S. PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 29.CANADA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 30.CANADA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 31.CANADA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 32.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 33.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 34.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 35.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 36.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 37.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 38.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 39.UK PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 40.UK PAIN MANAGEMENT DRUGS MARKET , BY INDICATION, 2019–2027 ($MILLION)
TABLE 41.UK PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 42.GERMANY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 43.GERMANY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 44.GERMNAY PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 45.FRANCE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 46.FRNACE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 47.FRANCE PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 48.ITALY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 49.ITALY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 50.ITALY PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 51.SPAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 52.SPAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 53.SPAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 54.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 55.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 56.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 57.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 58.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 59.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 60.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 61.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 62.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 63.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 64.CHINA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 65.CHINA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 66.CHINA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 67.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 68.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 69.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 70.INDIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 71.INDIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 72.INDIA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 76.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 77.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 78.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 79.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 80.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 81.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 82.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 83.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 84.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 85.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 86.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 87.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 88.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 89.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 90.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 91.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 92.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 93.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 94.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 95.ABBOTT: COMPANY SNAPSHOT
TABLE 96.ABBOTT: OERATING SEGMENT
TABLE 97.ABBOTT: PRODUCT PORTFOLIO
TABLE 98.ELI LILLY: COMPANY SNAPSHOT
TABLE 99.LILLY: OPERATING SEGMENTS
TABLE 100.ELI LILLY: PRODUCT PORTFOLIO
TABLE 101.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102.ENDO: COMPANY SNAPSHOT
TABLE 103.ENDO: OPERATING BUSINESS SEGMENTS
TABLE 104.ENDO: PRODUCT PORTFOLIO
TABLE 105.GSK: COMPANY SNAPSHOT
TABLE 106.GSK: OPERATING SEGMENTS
TABLE 107.GSK: PRODUCT PORTFOLIO
TABLE 108.J&J: COMPANY SNAPSHOT
TABLE 109.J&J: OPERATING BUSINESS SEGMENTS
TABLE 110.J&J: PRODUCT PORTFOLIO
TABLE 111.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 112.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 113.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 114.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 115.MYLAN: COMPANY SNAPSHOT
TABLE 116.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 117.MYLAN: PRODUCT PORTFOLIO
TABLE 118.NOVARTIS: COMPANY SNAPSHOT
TABLE 119.NOVARTIS: OPERATING SEGMENTS
TABLE 120.NOVARTIS: PRODUCT PORTFOLIO
TABLE 121.PFIZER: COMPANY SNAPSHOT
TABLE 122.PFIZER: OERATING SEGMENT
TABLE 123.PFIZER: PRODUCT PORTFOLIO
TABLE 124.PURDUE: COMPANY SNAPSHOT
TABLE 125.PURDUE: PRODUCT PORTFOLIO
TABLE 01.PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 02.PAIN MANAGEMENT DRUGS MARKET, BY NSAIDS, BY REGION, 2019–2027 ($MILLION)
TABLE 03.PAIN MANAGEMENT DRUGS MARKET, BY ANESTHETIC, BY REGION, 2019–2027 ($MILLION)
TABLE 04.PAIN MANAGEMENT DRUGS MARKET, BY ANTICONVULSANT, BY REGION, 2019–2027 ($MILLION)
TABLE 05.PAIN MANAGEMENT DRUGS MARKET, BY ANTIMIGRAINE DRUG, BY REGION, 2019–2027 ($MILLION)
TABLE 06.PAIN MANAGEMENT DRUGS MARKET, BY ANTIDEPRESSANT DRUGS, BY REGION, 2019–2027 ($MILLION)
TABLE 07.PAIN MANAGEMENT DRUGS MARKET, BY OPIOIDS, BY REGION, 2019–2027 ($MILLION)
TABLE 08.PAIN MANAGEMENT DRUGS MARKET, BY NON-NARCOTIC ANALGESICS, BY REGION, 2019–2027 ($MILLION)
TABLE 09.PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 10.PAIN MANAGEMENT DRUGS MARKET, BY ARTHMITIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 11.PAIN MANAGEMENT DRUGS MARKET, BY NEUROPATHIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 12.PAIN MANAGEMENT DRUGS MARKET, BY CANCER PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 13.PAIN MANAGEMENT DRUGS MARKET, BY CHRONIC BACK PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 14.PAIN MANAGEMENT DRUGS MARKET, BY POST-OPERATIVE PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 15.PAIN MANAGEMENT DRUGS MARKET, BY MIGRAINE, BY REGION, 2019–2027 ($MILLION)
TABLE 16.PAIN MANAGEMENT DRUGS MARKET, BY FIBROMYALGIA, BY REGION, 2019–2027 ($MILLION)
TABLE 17.PAIN MANAGEMENT DRUGS MARKET, BY BONE FRACTURE, BY REGION, 2019–2027 ($MILLION)
TABLE 18.PAIN MANAGEMENT DRUGS MARKET, BY MUSCLE SPRAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 19.PAIN MANAGEMENT DRUGS MARKET, BY ACUTE APPENDICITIS, BY REGION, 2019–2027 ($MILLION)
TABLE 20.PAIN MANAGEMENT DRUGS MARKET, BY OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 21.PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 22.PAIN MANAGEMENT DRUGS MARKET, BY CHRONIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 23.PAIN MANAGEMENT DRUGS MARKET, BY ACUTE PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 24.GLOBAL PAIN MANAGEMENT DRUGS MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 25.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 26.U.S. PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 27.U.S. PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 28.U.S. PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 29.CANADA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 30.CANADA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 31.CANADA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 32.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 33.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 34.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 35.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 36.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 37.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 38.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 39.UK PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 40.UK PAIN MANAGEMENT DRUGS MARKET , BY INDICATION, 2019–2027 ($MILLION)
TABLE 41.UK PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 42.GERMANY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 43.GERMANY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 44.GERMNAY PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 45.FRANCE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 46.FRNACE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 47.FRANCE PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 48.ITALY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 49.ITALY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 50.ITALY PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 51.SPAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 52.SPAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 53.SPAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 54.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 55.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 56.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 57.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 58.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 59.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 60.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 61.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 62.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 63.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 64.CHINA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 65.CHINA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 66.CHINA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 67.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 68.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 69.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 70.INDIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 71.INDIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 72.INDIA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 76.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 77.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 78.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 79.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 80.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 81.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 82.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 83.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 84.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 85.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 86.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 87.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 88.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 89.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 90.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 91.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 92.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 93.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 94.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 95.ABBOTT: COMPANY SNAPSHOT
TABLE 96.ABBOTT: OERATING SEGMENT
TABLE 97.ABBOTT: PRODUCT PORTFOLIO
TABLE 98.ELI LILLY: COMPANY SNAPSHOT
TABLE 99.LILLY: OPERATING SEGMENTS
TABLE 100.ELI LILLY: PRODUCT PORTFOLIO
TABLE 101.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102.ENDO: COMPANY SNAPSHOT
TABLE 103.ENDO: OPERATING BUSINESS SEGMENTS
TABLE 104.ENDO: PRODUCT PORTFOLIO
TABLE 105.GSK: COMPANY SNAPSHOT
TABLE 106.GSK: OPERATING SEGMENTS
TABLE 107.GSK: PRODUCT PORTFOLIO
TABLE 108.J&J: COMPANY SNAPSHOT
TABLE 109.J&J: OPERATING BUSINESS SEGMENTS
TABLE 110.J&J: PRODUCT PORTFOLIO
TABLE 111.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 112.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 113.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 114.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 115.MYLAN: COMPANY SNAPSHOT
TABLE 116.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 117.MYLAN: PRODUCT PORTFOLIO
TABLE 118.NOVARTIS: COMPANY SNAPSHOT
TABLE 119.NOVARTIS: OPERATING SEGMENTS
TABLE 120.NOVARTIS: PRODUCT PORTFOLIO
TABLE 121.PFIZER: COMPANY SNAPSHOT
TABLE 122.PFIZER: OERATING SEGMENT
TABLE 123.PFIZER: PRODUCT PORTFOLIO
TABLE 124.PURDUE: COMPANY SNAPSHOT
TABLE 125.PURDUE: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.PAIN MANAGEMENT DRUGS MARKET SEGMENTATION
FIGURE 02.TOP WINNING STRATEGIES, 2017–2020
FIGURE 03.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2020
FIGURE 04.TOP WINNING STRATEGIES: BY YEAR, 2017–2020
FIGURE 05.TOP PLAYER POSTIONING, 2019
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODEARTE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE COMPETITIVE OF RIVALRY
FIGURE 11.DRIVER, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NSAIDS BY COUNTRY, 2019 & 2027 (%)
FIGURE 13.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANESTHETIC BY COUNTRY, 2019 & 2027 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTICONVULSANT BY COUNTRY, 2019 & 2027 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTIMIGRAINE BY COUNTRY, 2019 & 2027 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTIDEPRESSANT DRUGS BY COUNTRY, 2019 & 2027 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR OPIOIDS BY COUNTRY, 2019 & 2027 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NON-NARCOTIC ANALGESICS BY COUNTRY, 2019 & 2027 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ARTHMITIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR CANCER PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC BACK PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR POST-OPERATIVE PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR MIGRAINE, BY COUNTRY, 2019 & 2027 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR FIBROMYALGIA BY COUNTRY, 2019 & 2027 (%)
FIGURE 26.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR BONE FRACTURE BY COUNTRY, 2019 & 2027 (%)
FIGURE 27.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR MUSCLE SPRAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 28.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE APPENDICITIS BY COUNTRY, 2019 & 2027 (%)
FIGURE 29.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR OTHERS BY COUNTRY, 2019 & 2027 (%)
FIGURE 30.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 31.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 32.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 33.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 34.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 35.ELI LILLY: NET SALES, 2017–2019 ($MILLION)
FIGURE 36.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 37.ENDO: NET SALES, 2017–2019 ($MILLION)
FIGURE 38.ENDO: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 39.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 40.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 41.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 42.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 43.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 44.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 45.MERCK & CO., INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 46.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 47.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 48.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 49.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 50.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 51.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 52.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 53.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 54.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 55.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 01.PAIN MANAGEMENT DRUGS MARKET SEGMENTATION
FIGURE 02.TOP WINNING STRATEGIES, 2017–2020
FIGURE 03.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2020
FIGURE 04.TOP WINNING STRATEGIES: BY YEAR, 2017–2020
FIGURE 05.TOP PLAYER POSTIONING, 2019
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODEARTE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE COMPETITIVE OF RIVALRY
FIGURE 11.DRIVER, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NSAIDS BY COUNTRY, 2019 & 2027 (%)
FIGURE 13.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANESTHETIC BY COUNTRY, 2019 & 2027 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTICONVULSANT BY COUNTRY, 2019 & 2027 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTIMIGRAINE BY COUNTRY, 2019 & 2027 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTIDEPRESSANT DRUGS BY COUNTRY, 2019 & 2027 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR OPIOIDS BY COUNTRY, 2019 & 2027 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NON-NARCOTIC ANALGESICS BY COUNTRY, 2019 & 2027 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ARTHMITIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR CANCER PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC BACK PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR POST-OPERATIVE PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR MIGRAINE, BY COUNTRY, 2019 & 2027 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR FIBROMYALGIA BY COUNTRY, 2019 & 2027 (%)
FIGURE 26.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR BONE FRACTURE BY COUNTRY, 2019 & 2027 (%)
FIGURE 27.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR MUSCLE SPRAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 28.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE APPENDICITIS BY COUNTRY, 2019 & 2027 (%)
FIGURE 29.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR OTHERS BY COUNTRY, 2019 & 2027 (%)
FIGURE 30.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 31.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 32.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 33.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 34.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 35.ELI LILLY: NET SALES, 2017–2019 ($MILLION)
FIGURE 36.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 37.ENDO: NET SALES, 2017–2019 ($MILLION)
FIGURE 38.ENDO: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 39.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 40.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 41.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 42.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 43.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 44.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 45.MERCK & CO., INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 46.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 47.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 48.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 49.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 50.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 51.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 52.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 53.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 54.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 55.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
